Ventrus Biosciences, Inc.
VTUS announced today that it is concurrently offering to sell,
subject to market and other conditions, (i) shares of its common stock in an
underwritten public offering, and (ii) shares of its Series A Convertible
Preferred Stock ("Series A") in a separate underwritten public offering. The
Series A is non-voting and each share of Series A is convertible into 10
shares of Ventrus common stock, provided that conversion will be prohibited
if, as a result, the holder and its affiliates would own more than 9.98% of
the total number of Ventrus shares of common stock then outstanding. All of
the shares in these offerings are to be sold by Ventrus. Ventrus also intends
to grant the underwriter a 30-day option to purchase up to an additional 15%
of the shares of common stock sold in the common stock public offering to
cover over-allotments, if any.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in